Home Self-Administration of Biologics – A German Survey among Omalizumab-Treated Patients with Severe Asthma and their Treating Physicians

Abstract

In the EU, five biologics have been approved as add-on therapy for patients with severe asthma. Until recently, none of the biologics was approved for home use and had to be administered under medical supervision, a time-consuming schedule for both patients and physicians, accompanied by greater expenditure. However, over the last year, four out of the five biologics have been granted approval for patient self-administration at home. The objective of this multiple-choice survey was to understand how patients with severe asthma treated with omalizumab and their treating physicians view the potential home use of biologics exemplified by omalizumab. The questionnaires were answered by 120 physicians and 432 patients (response rate: 51.7 % and 20.6 %, respectively). Overall, 44.7 % of patients were in favour of self-administration at home while 30.6 % opposed this method of administration and 23.8 % of patients were neutral. Especially teenagers and young adults had a positive attitude towards self-administration. 76.7 % of the questioned physicians were in favour of home use for certain patients. Time saving was the main advantage for self-administration mentioned by patients (53.2 %) as well as by physicians (72.5 %). The main concern for patients was ‘making a mistake while injecting’ (43.8 %) while ‘forgetting to inject omalizumab’ (73.3 %) was the main concern for physicians. 44.4 % of patients expressed a wish for individual training and 70.8 % of physicians agreed with this statement. The latter group also considered a starter kit including several information materials (54.2 %) as well as an electronic reminder system (50.8 %) as useful. In conclusion, self-administration of biologics has the potential to be timesaving for both patients and physicians.

Zusammenfassung

In der EU sind derzeit 5 Biologika als Add-on-Behandlung bei schwerem Asthma zugelassen. Bisher musste die Administration unter medizinischer Aufsicht erfolgen, was sowohl für Patienten als auch Arztpraxen mit einem erhöhten Zeit- und Kostenaufwand einhergeht. Im Laufe des letzten Jahres wurde allerdings die Selbstapplikation für 4 der 5 Biologika zugelassen. Ziel dieser Umfrage war es, mittels Multiple-Choice-Fragebögen das Potenzial einer Selbstapplikation von Biologika aus der Sicht von Patienten und Ärzten am Beispiel von Omalizumab einzuschätzen. In die Auswertung flossen 432 Patienten- und 120 Ärzte-Fragebögen ein (Rücklaufquote: 51,7 % bzw. 20,6 %). Insgesamt bewerteten 44,7 % der Patienten eine Selbstapplikation positiv, 30,6 % ablehnend und 23,8 % neutral. V. a. in den Altersgruppen der Jugendlichen und jungen Erwachsenen wurde eine Selbstapplikation überwiegend positiv bewertet. 76,7 % der befragten Ärzte würden eine Selbstapplikation für bestimmte Patienten befürworten. Als wichtigster Vorteil wurde bei Patienten bzw. Ärzten v. a. die Zeitersparnis (53,2 % bzw. 72,5 %) genannt. Bedenken äußerten die Patienten v. a. zu Fehlern beim Spritzen (43,8 %), während bei Ärzten am häufigsten „vergessen Omalizumab zu spritzen“ (73,3 %) genannt wurde. Von 44,4 % der Patienten wurde der Wunsch nach einer persönlichen Schulung zur Selbstapplikation als Unterstützung geäußert, während bei den Ärzten neben dieser Unterstützung (70,8 %) v. a. auch ein Starterkit mit verschiedensten Infomaterialien (54,2 %) sowie ein elektronisches Erinnerungs-System (App) als sinnvoll erachtet wurden (50,8 %). Zusammenfassend ergab die Umfrage, dass die praxisexterne Selbstapplikation von Biologika sowohl bei Patienten als auch Ärzten überwiegend befürwortet wurde und zu einer Zeitersparnis beitragen kann.

• References

• 1 Chung KF, Wenzel SE, Brozek JL. et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343-373
• 2 Cox L, Platts-Mills TA, Finegold I. et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007; 120: 1373-1377
• 3 Bel EH, Bernstein DI, Bjermer L. et al. Usability of mepolizumab single-use prefilled syringe for patient self-administration. J Asthma 2019;
• 4 Bernstein D, Pavord ID, Chapman KR. et al. Usability of mepolizumab single-use prefilled autoinjector for patient self-administration. J Asthma 2019;
• 5 Ferguson GT, Mansur AH, Jacobs JS. et al. Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthma. J Asthma Allergy 2018; 11: 63-72
• 6 Liebhaber M, Dyer Z. Home therapy with subcutaneous anti-immunoglobulin-E antibody omalizumab in 25 patients with immunoglobulin-E-mediated (allergic) asthma. J Asthma 2007; 44: 195-196
• 7 Busse W, Corren J, Lanier BQ. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184-190
• 8 Busse WW, Massanari M, Kianifard F. et al. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. Curr Med Res Opin 2007; 23: 2379-2386
• 9 Chupp GL, Bradford ES, Albers FC. et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 2017; 5: 390-400
• 10 Castro M, Zangrilli J, Wechsler ME. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3: 355-366
• 11 FitzGerald JM, Bleecker ER, Nair P. et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 388: 2128-2141
• 12 Wenzel S, Castro M, Corren J. et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016; 388: 31-44
• 13 Collier DH, Bitman B, Coles A. et al. A novel electromechanical autoinjector, AutoTouch, for self-injection of etanercept: real-world use and benefits. Postgrad Med 2017; 129: 118-125
• 14 Gottlieb AB, Blauvelt A, Prinz JC. et al. Secukinumab self-administration by prefilled syringe maintains reduction of plaque psoriasis severity over 52 weeks: Results of the FEATURE trial. J Drugs Dermatol 2016; 15: 1226-1234
• 15 Abolhassani H, Sadaghiani MS, Aghamohammadi A. et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol 2012; 32: 1180-1192
• 16 Denman S, Ford K, Toolan J. et al. Home self-administration of omalizumab for chronic spontaneous urticaria. Br J Dermatol 2016; 175: 1405-1407
• 17 Chilton F, Collett RA. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care 2008; 6: 1-14
• 18 Devonshire VA, Feinstein A, Moriarty P. Adherence to interferon beta-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study. BMC Res Notes 2016; 9: 148
• 19 Katz SJ, Leung S. Teaching methotrexate self-injection with a web-based video maintains patient care while reducing healthcare resources: a pilot study. Rheumatol Int 2015; 35: 93-96
• 20 Dayer L, Heldenbrand S, Anderson P. et al. Smartphone medication adherence apps: potential benefits to patients and providers. J Am Pharm Assoc 2013; 53: 172-181
• 21 Di Bona D, Fiorino I, Taurino M. et al. Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study. Respir Med 2017; 130: 55-60
• 22 Lieberman PL, Umetsu DT, Carrigan GJ. et al. Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study. J Allergy Clin Immunol 2016; 138: 913-915.e912